© 2019 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct two Phase I clinical studies

17.11.2017

In early November, IPHARMA received two approvals from the Ministry of Health of the Russian Federation to conduct phase I clinical trials of Ventvil® and Slavinorm® medicinal products.

 

Protocol № HEP-VTL-01 "A double-blind, randomized, placebo-controlled study of the safety and tolerability of increasing doses of Ventvil® for single and subsequent multiple intramuscular administration in healthy volunteers."

 

The study objective is to evaluate the safety and tolerability of increasing doses of the drug with a single and subsequent multiple intramuscular administration in healthy volunteers.

 

Domain of usage: therapy, hepatic disorders.

 

Protocol No. CNS-SNM-01 "A double-blind, randomized, placebo-controlled study of the safety and tolerability of increasing doses of Slavinorm® for single and subsequent multiple intramuscular administration in healthy volunteers."

 

The study objective is to assessthe safety and tolerability of increasing doses of the drug with a single and subsequent multiple intramuscular administration in healthy volunteers.

 

Domain of usage: neurology (angioprotector).

 

Ventvil® and Slavinorm® are developed by the SIA Peptides company. It is a complex of polypeptides extracted from the organs and horns of cattle.

Tags:

Please reload

Недавние посты
Please reload

Архив
Please reload